J&J’s Q1 Earnings: Strong Drug Sales Offset by Tariff Concerns
The healthcare subsidiary Johnson & Johnson (J&J) has posted its first-quarter earnings, which contain a beneficial revenue report on ‘drug sales’ but an unfavorable outlook scared by the impact of tariffs by the Trump administration. Although its earnings surprisingly surpass Wall Street’s expectations, the potential trade disruption risks are still far from the radar. Earnings…
